Cardiology Pharmaceuticals

SPORT: Statins Obliterate OTC Heart Supplements

Rosuvastatin 5 mg daily lowered LDL-C levels more than fish oil, cinnamon, garlic, turmeric, red yeast rice, and placebo in those with increased 10-year risk for ASCVD, according to a recent study presented at AHA 2022. 

Over-the-counter heart supplements claim to fight cholesterol and promote heart health, and many Americans subscribe to the hype. The study’s lead author Luke Laffin, MD explained that 75% of Americans take at least one dietary supplement, and 18% percent take a supplement to promote heart function. 

Laffin’s findings challenge the multibillion dollar industry. 

In the study, researchers looked at data from 200 adults with no history of cardiovascular disease, but who had a 5-20% risk of developing ASCVD within 10 years. Researchers randomly assigned participants to one of eight groups: placebo, rosuvastatin (5 mg), fish oil (2400 mg), cinnamon (2400 mg), garlic (with 5000 mcg of allicin), turmeric (3500 mg), plant sterols (1600 mg), and red yeast rice (2400 mg). 

LDL-C levels decreased in the following groups at 28 days: 

  • Rosuvastatin: -38%
  • Placebo: -2.6%
  • Fish oil: -3.4%
  • Turmeric: -1.3% 
  • Plant sterols: -4.37%
  • Red yeast rice: -6.5%

LDL-C levels actually increased in people taking these supplements: 

  • Cinnamon: +0.4%
  • Garlic: +5.1%

The Takeaway 

Six widely used dietary supplements promoted for improving heart health – including brands of fish oil, cinnamon, garlic, and turmeric – were not as effective as rosuvastatin at lowering LDL cholesterol. Statins are still the cholesterol kingpin. As cardiologists have been saying for decades (and as they made clear on twitter), supplements cannot take the place of an effective statin. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!